Xiamen Amoytop Biotech Co. Ltd. engages in the research and development of genetic engineering technology. It develops recombinant protein drugs such as rHuGM-CSF, rHuG-CSF, rHuIL-11, rHuIFN a-2a and rHuIFN a-2b.The company's products include Molgramostim, Filgrastim, and Oprelvekin. Xiamen Amoytop Biotech was founded on August 7, 1996 and is headquartered in Xiamen, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company